Long COVID and hypertension-related disorders: a report from the Japanese Society of Hypertension Project Team on COVID-19

Matsumoto, Chisa; Shibata, Shigeru; Kishi, Takuya; Morimoto, Satoshi; Mogi, Masaki; Yamamoto, Kōichi; Kobayashi, Kazuo; Tanaka, Masami; Asayama, Kei; Yamamoto, Eiichiro; Nakagami, Hironori; Hoshide, Satoshi; Mukoyama, Masashi; Kario, Kazuomi; Node, Koichi; Rakugi, Hiromi

doi:10.1038/s41440-022-01145-2

Cited by 34 publications

(28 citation statements)

References 193 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Currently, pathophysiological mechanisms potentially involved in the onset of new HT remains poorly understood. However, it seems that viral persistence, delayed resolution of inflammation or residual organ damage after the acute phase of infection as well as renin-angiotensin-aldosterone system (RAAS) dysregulation and previous autoimmune conditions, may represent potential contributors, alone or together [24][25][26]. From our data it seems that females sex influences the risk of new-onset HT sequalae after COVID-19 infection.…”

Section: Discussionmentioning

confidence: 79%

Risk of Incident New-Onset Arterial Hypertension After COVID-19 Recovery: A Systematic Review and Meta-analysis

Zuin

Rigatelli

Bilato³

et al. 2023

High Blood Press Cardiovasc Prev

View full text Add to dashboard Cite

Introduction Arterial Hypertension (HT) has been described as a common comorbidity and independent risk factor of short-term outcome in COVID-19 patients. However, data regarding the risk of new-onset HT during the post-acute phase of COVID-19 are scant. Aim We assess the risk of new-onset HT in COVID-19 survivors within one year from the index infection by a systematic review and meta-analysis of the available data. Methods Data were obtained searching MEDLINE and Scopus for all studies published at any time up to February 11, 2023, and reporting the long-term risk of new-onset HT in COVID-19 survivors. Risk data were pooled using the Mantel–Haenszel random effects models with Hazard ratio (HR) as the effect measure with 95% confidence interval (CI). Heterogeneity among studies was assessed using I 2 statistic. Results Overall, 19,293,346 patients (mean age 54.6 years, 54.6% males) were included in this analysis. Of them, 758,698 survived to COVID-19 infection. Over a mean follow-up of 6.8 months, new-onset HT occurred to 12.7 [95% CI 11.4–13.5] out of 1000 patients survived to COVID-19 infection compared to 8.17 [95% CI 7.34–8.53] out of 1000 control subjects. Pooled analysis revealed that recovered COVID-19 patients presented an increased risk of new-onset HT (HR 1.70, 95% CI 1.46–1.97, p < 0.0001, I 2 = 78.9%) within seven months. This risk was directly influenced by age (p = 0.001), female sex (p = 0.03) and cancer (p < 0.0001) while an indirect association was observed using the follow-up length as moderator (p < 0.0001). Conclusions Our findings suggest that new-onset HT represents an important post-acute COVID-19 sequelae. Supplementary Information The online version contains supplementary material available at 10.1007/s40292-023-00574-5.

show abstract

Section: Discussionmentioning

confidence: 79%

Risk of Incident New-Onset Arterial Hypertension After COVID-19 Recovery: A Systematic Review and Meta-analysis

Zuin

Rigatelli

Bilato³

et al. 2023

High Blood Press Cardiovasc Prev

View full text Add to dashboard Cite

show abstract

“…Post-acute sequelae of COVID-19, also called long COVID, has increasingly been recognized worldwide [4]. In a realtime tracking based on a mobile application in April 2020, 558 out of 4182 (13.3%) COVID-19 patients in the UK reported symptoms that lasted for ≥ 28 days, including fatigue, headache, dyspnea, and anosmia [34].…”

Section: Hypertension and Long Covidmentioning

confidence: 99%

“…Emerging evidence indicate that cardiovascular complications can occur as a post-acute sequela of COVID-19 [4]. Using national healthcare databases from the US Department of Veterans Affairs, Xie et al built a cohort of 153,760 individuals with positive for COVID-19 testing between March 2020 and January 2021 (Table 1) [39].…”

Section: Is Hypertension a Post-acute Sequela Of Covid-19?mentioning

confidence: 99%

See 1 more Smart Citation

COVID-19 pandemic and hypertension: an updated report from the Japanese Society of Hypertension project team on COVID-19

et al. 2022

View full text Add to dashboard Cite

The number of reported cases with coronavirus disease 2019 (COVID-19) has exceeded 620 million worldwide, still having a profound impact on people's health and daily lives since its occurrence and outbreak in December 2019. From the early phase of the COVID-19 pandemic, there has been a concern that the rapid spread of this communicable disease can negatively influence non-communicable diseases. Accumulating data indicate that the restriction on the access to medical care, psychological distress, and life-style changes triggered by the pandemic have indeed affected blood pressure control in hypertensive patients. Since our previous report in 2020 that summarized the findings of the literature related to COVID-19 and hypertension, there has been a considerable progress in our understanding of the association between these two disorders; nonetheless, there are remaining challenges and emerging questions in the field. In this article, we aim to summarize the latest information on the impact of the pandemic on blood pressure control, the use of the renin-angiotensin system inhibitors in patients with COVID-19, and the blood pressure changes as one of the possible post-acute sequelae of COVID-19 (also known as long COVID). We also summarize the evidence of telemedicine and COVID-19 vaccination in hypertensive subjects, based on data available as of June 2022.

show abstract

“…Hypertension, a nearly ubiquitous complication in HD patients, has been identi ed as a risk factor for COVID-19 and is hypothesized to be a potential risk factor for long COVID [7]. Interleukins (IL)-6 and -17 have been shown to play an important role in both the severity of COVID- 19 [8, 9] and the promotion of hypertension [10,11].…”

Section: Introductionmentioning

confidence: 99%

IL-6 and IL-17 may provide a potential link between hypertension and long-COVID sequelae in hemodialysis patients: A multicenter cross-sectional study

Stepanova

Driianska

Rysyev³

et al. 2023

Preprint

View full text Add to dashboard Cite

Objective The mechanisms underlying long COVID in patients treated with hemodialysis (HD) are not yet fully understood. We hypothesized that uncontrolled blood pressure (BP) before infection might contribute to the development of long-COVID symptoms in HD patients through upregulation of interleukin (IL)-6 and IL-17 production, possibly associated with severe acute COVID-19. In the present cross-sectional study, we examined serum IL-6 and IL-17 levels at two time points after acute COVID-19 infection taking into account preinfection BP and the presence of long-COVID sequelae in HD patients. Results A total of 80 HD patients aged 56 (44–63.2) years with a dialysis vintage of 4.7 (3.3 − 7.08) years who had experienced COVID-19 at least 5 months before enrollment were included in this cross-sectional study. We found that preinfection uncontrolled BP was associated with long-COVID sequelae in HD patients. Both hypertension and long COVID resulted in elevated IL-6 and IL-17 concentrations, peaking in patients with both conditions and decreasing over time after COVID-19 possibly reflecting Th17-related systemic inflammation during the acute phase of COVID-19.

show abstract

Long COVID and hypertension-related disorders: a report from the Japanese Society of Hypertension Project Team on COVID-19

Cited by 34 publications

References 193 publications

Risk of Incident New-Onset Arterial Hypertension After COVID-19 Recovery: A Systematic Review and Meta-analysis

Risk of Incident New-Onset Arterial Hypertension After COVID-19 Recovery: A Systematic Review and Meta-analysis

COVID-19 pandemic and hypertension: an updated report from the Japanese Society of Hypertension project team on COVID-19

IL-6 and IL-17 may provide a potential link between hypertension and long-COVID sequelae in hemodialysis patients: A multicenter cross-sectional study

Contact Info

Product

Resources

About